An orally active peptide variant of hGH 177-191, called AOD9604, was shown to stimulate metabolism of fat in animal trials [88,89] but, after a phase IIB clinical trial, the results did not support the commercial viability of the drug as a treatment for obesity. Here, GH1 is linked to obesity disorder.